Advertisement

Multiorganinfektionen — komplexe klinisch-infektiologische Krankheiten

  • Frank Bergmann
  • Ulrich Bienzle
  • Henning Breithaupt
  • Friedrich Grimminger
  • Jürgen Lohmeyer
  • D. Schürmann
  • Werner Seeger
  • Norbert Suttorp
  • Hans-Dieter Walmrath
Chapter
  • 58 Downloads

Literatur

Literatur

  1. Abraham E (2000) Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 22: 401–404PubMedGoogle Scholar
  2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310PubMedGoogle Scholar
  3. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinat human activated protein C for severe sepsis. N Engl J Med 344: 699–709CrossRefPubMedGoogle Scholar
  4. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26: 645–650PubMedGoogle Scholar
  5. Bozzette S, Sattler F, Chiu J et al. (1990) A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323: 1451–1457PubMedGoogle Scholar
  6. Briegel J, Forst H, Haller M et al. (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 27: 723–732PubMedGoogle Scholar
  7. Cronin L, Cook DJ, Carlet J (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23: 1430–1439PubMedGoogle Scholar
  8. Lefering R, Neugebauer EAM (1995) Steroid controversy in sepsis and septic shock: a meta.analysis. Crit Care Med 23: 1294–1303PubMedGoogle Scholar
  9. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301–1308CrossRefGoogle Scholar

Literatur

  1. Adal KA, Cockerell CI, Petri WA Jr (1994) Cat scratch disease, bacillary angiomatosis and other infections due to Rochalimaea. N Engl J Med 350: 1509Google Scholar
  2. Ariza JF et al. (1992) Treatment of human brucellosis with doxycycline plus rifampine or doxycycline plus streptomycin: a randomized double blind study. Ann Intern Med 117: 25PubMedGoogle Scholar
  3. Centers for Disease Control and Prevention (1998) 1998 sexually transmitted disease treatment guidelines. MMWR 147: 28Google Scholar
  4. Cohen JI (2000) Epstein Barr Virus Infection. N Engl J Med 343: 481–492CrossRefPubMedGoogle Scholar
  5. Cox NJ, Hughes JM (1999) New options for the prevention of influenza. N Engl J Med 342: 1387Google Scholar
  6. Dattwyler RJ et al. (1997) Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 337: 289CrossRefPubMedGoogle Scholar
  7. Franz DR et al. (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278: 5CrossRefGoogle Scholar
  8. Hof H, Nichterlein T, Kretschmar M (1997) Management of Listeriosis. Clin Microbiol Rev 10: 345PubMedGoogle Scholar
  9. Kuntz P, Pieringer-Müller E, Hof H (1996) Infektionsgefährdung durch Bissverletzungen. Dtsch Ärztebl 93: B 765–768Google Scholar
  10. Nadal D, Zbinden R (1996) Erkrankungen durch Bartonellen. Internist 37: 890–894PubMedGoogle Scholar
  11. Priem S, Franz J, Krause A (1999) Ätiologie und Pathogenese bakteriell bedingter Arthritiden. Infektiöse Arthritis, reaktive Arthritis, Lyme-Arthritis. Internist 40: 936–944CrossRefPubMedGoogle Scholar
  12. Sander A, Kalibe T, Bredt W (1996) Bartonella (Rochalimaea)-Infektionen: Katzenkratzkrankheit und bazilläre Angiomatose. Dtsch Med Wochenschr 121: 65–69PubMedGoogle Scholar
  13. Simon C, Stille W (1999) Antibiotika-Therapie in Klinik und Praxis, 10. Aufl. Schattauer, StuttgartGoogle Scholar
  14. Small PM, Fujiwara PI (2001) Management of tuberculosis in the United States. N Engl J Med 345: 189–200CrossRefPubMedGoogle Scholar
  15. Smith JW, Hasan MS (2000) Infectious Arthritis. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, 1175–1182Google Scholar
  16. Steere AC (2001) Lyme Disease. N Engl J Med 345: 115–125CrossRefPubMedGoogle Scholar

Literatur

  1. Blockmans D, Knockaert D, Maes A, de Caestecker J, Stroobants S, Bobbaers H, Mortelmans L (2001) Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 32: 191CrossRefPubMedGoogle Scholar
  2. Cunha BA (1996) Fever of unknown origin. Infect Dis Clin North Am 10: 111PubMedGoogle Scholar
  3. Hirschmann JV (1997) Fever of unknown origin in adults. Clin Infect Dis 24: 291PubMedGoogle Scholar
  4. Hughes WT, Armstrong D, Bodey GP et al. (Infectious Diseases Society of America) (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25(3): 551–573PubMedGoogle Scholar
  5. Petersdorf RC, Beeson PB (1996) Fever of unexplained origin. Medicine 40: 1Google Scholar
  6. Pizzo PA (1999) Fever in immunocompromised patients. N Engl J Med 341(12): 893–900CrossRefPubMedGoogle Scholar

Literatur

  1. Akerele T, Lightman S (1999) Current and novel agents for the treatment of cytomegalovirus retinitis.⁢ Drugs R D 2(5): 289–297PubMedGoogle Scholar
  2. Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338: 1741PubMedGoogle Scholar
  3. Freifeld A, Marchigiani D, Walsh T et al. (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341(5): 305–311CrossRefPubMedGoogle Scholar
  4. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control 20: 271–274CrossRefPubMedGoogle Scholar
  5. Ozer H, Armitage JO, Bennett CL et al. (American Society of Clinical Oncology Growth Factors Expert Panel) (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18(20): 3558–3585PubMedGoogle Scholar

Literatur

  1. American Thoracic Society (1996) Hospital acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care Med 153:1711–1725Google Scholar
  2. Raad I (1998) Intravascular catheter related infections. Lancet 351: 893–898CrossRefPubMedGoogle Scholar
  3. Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27:887–892PubMedGoogle Scholar
  4. Warren JW (1997) Catheter-associated urinary tract infection. Infect Dis Clin North Am 11:609–620CrossRefPubMedGoogle Scholar

Literatur

  1. Bozzette S, Sattler F, Chiu J et al. (1990) A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323: 1451–1457PubMedGoogle Scholar
  2. Brodt H-R, Helm EB, Kamps BS (2000) AIDS 2000. Steinhäuser, Wuppertal-BeyenburgGoogle Scholar
  3. Buchbinder SP, Katz MH, Hessol NA, O’Malley PM, Holmberg SD (1994) Long-term HIV-1 infection without immunologic progression. AIDS 8: 1123–1128PubMedGoogle Scholar
  4. Chene G, Sterne JA, May M et al., Antiretroviral Therapy Cohort Collaboration (2003) Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679–686PubMedGoogle Scholar
  5. Cingolani A, Antinori A, Rizzo MG et al. (2002) Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16: 369–379CrossRefPubMedGoogle Scholar
  6. Clavel F, Hance AJ (2004) HIV drug resistance. N Eng J Med 350: 1023–1035Google Scholar
  7. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 355: 1131–1137Google Scholar
  8. Davey RT et al. (2000) Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA 284: 183–189CrossRefPubMedGoogle Scholar
  9. Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. Aktualisierung Mai 2003. http://www.rki.de/infekt/aids_std/br_linie/br_linie.htmGoogle Scholar
  10. Dragsted UB, Gerstoft J, Pedersen C et al., MaxCmin1 Trial Group (2003) Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 188: 635–642CrossRefPubMedGoogle Scholar
  11. Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A (2000) Selective referral to high-volume hospitals: estimating potentially avoidable deaths. JAMA 283: 1159–1166CrossRefPubMedGoogle Scholar
  12. Egger M, May M, Chene G et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. 360: 119–129Google Scholar
  13. Fagard C, Oxenius A, Gunthard H et al., Swiss HIV Cohort Study (2003) A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163: 1220–1226CrossRefPubMedGoogle Scholar
  14. German-Austrian guidelines for antiretroviral therapy in HIV infection. June 1999. Eur J Med Res 5: 129–138Google Scholar
  15. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004. http://aidsinfo.nih.gov/guidelines/adult/AA_032304.htmlGoogle Scholar
  16. Hengel R, Kovacs J (2003) Surrogate markers of immune function in human immunodeficiency virus-infected patients: what are they surrogates for? JID 188: 1791–1793PubMedGoogle Scholar
  17. Hoen B, Fournier I, Charreau I, Lacabaratz C, Burgard M et al. (2004) Structured treatment interruptions in primary HIV infection: final results of the multicenter prospective PRIMSTOP pilot trial. 11th CROI, San Francisco 2004, Abstract 395Google Scholar
  18. Hoffmann C, Kamps BS (2004) HIV.NET 2004. Steinhäuser, Wuppertal-BeyenburgGoogle Scholar
  19. Jouan M, Saves M, Tubiana R et al. (2001) Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. RESTIMOP study team. AIDS 15: 23–31PubMedGoogle Scholar
  20. Kaplan EJ, Masur H, Holmes KK (2000) Prevention of opportunistic infections in persons infected with HIV. CID 30[Suppl 1]: 1–93Google Scholar
  21. Kaufmann D, Lichterfeld M, Altfeld M, Allen T, Johnston M et al. (2004) Limited durability of immune control following treated acute HIV infection. 11th CROI, San Francisco, Abstract 24Google Scholar
  22. Kempf DJ, Rode RA, Xu Y et al. (1998) The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12: F9–F14CrossRefPubMedGoogle Scholar
  23. Kolson DL, Gonzalez-Scarano F (2000) HIV and HIV dementia. J Clin Invest 106: 11–13PubMedGoogle Scholar
  24. Korber B et al. (2000) Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789–1796CrossRefPubMedGoogle Scholar
  25. Kuritzkes D (2000) Viral pathogenesis: update and clinical implications. Medscape, zGoogle Scholar
  26. Lederman MM, Valdez H (2000) Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 284: 223–228CrossRefPubMedGoogle Scholar
  27. Letvin NL, Walker BD (2003) Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9: 861–866CrossRefPubMedGoogle Scholar
  28. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM et al. (2001) A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 344: 159–167PubMedGoogle Scholar
  29. Mallal SA, John M, Moore CB, James IR, McKinnon EJ (2000) Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14: 1309–1316PubMedGoogle Scholar
  30. Mallon PW, Ray J, Cooper DA (2003) Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 26: 223–227CrossRefPubMedGoogle Scholar
  31. Masur H, Kaplan JE, Holmes KK, U.S. Public Health Service; Infectious Diseases Society of America (2002) Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 137: 435–478.PubMedGoogle Scholar
  32. Mellors JW, Munoz A, Giorgi JV et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126: 946–954PubMedGoogle Scholar
  33. Mocroft A et al. (2000) AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 354: 291–296Google Scholar
  34. Mussini C et al. (2000) Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 181: 1635–1642CrossRefPubMedGoogle Scholar
  35. Nolan D (2003) Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63: 2555–2574CrossRefPubMedGoogle Scholar
  36. Norman C (2000) HIV and Africa’s future. Science 288: 2149CrossRefPubMedGoogle Scholar
  37. O’Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD (1997) Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 126: 939–945PubMedGoogle Scholar
  38. Palella FJ, Jr., Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860CrossRefPubMedGoogle Scholar
  39. Phillips AN, Cozzi Lepri A, Lampe F, Johnson M, Sabin CA (2003) When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 17: 1863–1869PubMedGoogle Scholar
  40. Postexpositionelle Prophylaxe nach HIV-Exposition. Deutsch-Österreichische Empfehlungen. Aktualisierung Mai 2002. http://www.rki.de/infekt/aids_std/expo/hiv.htmGoogle Scholar
  41. Robert-Koch-Institut (2004) HIV/AIDS-Bericht II/2003. Epidemiologisches Bulletin, Sonderausgabe AGoogle Scholar
  42. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37: 1112–1118CrossRefPubMedGoogle Scholar
  43. Shelburne SA 3rd, Hamill RJ (2003) The immune reconstitution inflammatory syndrome. AIDS Rev 5: 67–79PubMedGoogle Scholar
  44. Skidmore SJ, Zuckermann M, Parry JV (2000) Accuracy of plasma HIV RNA quantification: A multicenter study of variability. J Med Virol 61: 187–194CrossRefGoogle Scholar
  45. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J (2000) Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 14: 383–386PubMedGoogle Scholar
  46. Staszewski S, Morales-Ramirez J, Tashima KT et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341: 1865–1873CrossRefPubMedGoogle Scholar
  47. Stebbing J, Gazzard B, Douek DC (2004) Where does HIV live? N Engl J Med. 350: 1872–1880CrossRefPubMedGoogle Scholar
  48. The EuroGuidelines Group for HIV Resistance (2001) Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 15: 309–320Google Scholar
  49. Tsiodras S, Mantzoros C, Hammer S, Samore M (2000) Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 160: 2050–2056CrossRefPubMedGoogle Scholar
  50. Van Leeuwen R, Katlama C, Murphy RL et al. (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 17: 987–999PubMedGoogle Scholar
  51. van Leth F, Hassink E, Phanuphak P et al. (2003) Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either Nevirapine alone, Efavirenz alone or both drugs combined, together with Stavudine and Lamivudine. 10th CROI, Boston, Abstract 176Google Scholar
  52. Vanhems P et al. (2000) Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute hiv infection are independent prognostic factors of progression to AIDS. J Infect Dis 182: 334–337CrossRefPubMedGoogle Scholar
  53. Williams I, Asboe D, Babiker A et al. (2004) A virological benefit from an induction/maintenance strategy compared with a standard 3-drug regimen in antiretroviral naive patients: the FORTE trial. 11th CROI, San Francisco, Abstract 564Google Scholar
  54. Wood E, Hogg RS, Yip B, Harrigan PR, O’shaughnessy MV, Montaner JS (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 139: 810–816PubMedGoogle Scholar

Literatur

  1. Arbeitsgemeinschaft Wissenschaftliche Medizinische Fachgesellschaften (AWMF): Leitlinie zu Diagnostik und Therapie der Malaria. www.awmfleitlinien.deGoogle Scholar
  2. Burchard GD (Hrsg) (1998) Erkrankungen bei Immigranten. Diagnostik, Therapie, Begutachtung. Gustav Fischer, StuttgartGoogle Scholar
  3. Knobloch J (Hrsg) (1996) Tropen-und Reisemedizin. Gustav Fischer, StuttgartGoogle Scholar
  4. Lang W, Löscher T (Hrsg) (2000) Tropenmedizin in Klinik und Praxis. Thieme, StuttgartGoogle Scholar
  5. WHO (1995) Drugs used in parasitic diseases. WHO, GenfGoogle Scholar

Literatur

  1. Arbeitsgemeinschaft Peritonitis (PEG) (1983) Bakterielle Befunde bei verschiedenen Peritonitisformen. FAC 2/3: 423–429Google Scholar
  2. Bohnen JMA (1998) Antibiotic therapy for abdominal infection. World J Surg 22: 152–157CrossRefPubMedGoogle Scholar
  3. Häring R (1993) Peritonitis. Thieme, StuttgartGoogle Scholar
  4. Hau T, Ohmann C, Wolmershauser A, Wacha H (Group of the Surgical Infection Society of Europe) (1995) Planned relaparotomy versus relaparotomy on demand in the treatment of intraabdominal infections. Arch Surg 130: 1193–1197PubMedGoogle Scholar
  5. Hord CE (1995) Treatment of intraabdominal infections: worldwide clinical trials. Infect Dis Clin Pract 4: 17–25Google Scholar
  6. Levison ME, Bush LM (2000) Peritonitis and other intra-abdominal infections. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, p 821–856Google Scholar
  7. Schöffel U, Häring R, Farthmann EH (1993) Diagnose und Behandlungsstrategie intraabdomineller Abszesse. Zentralbl Chir 118: 303–308PubMedGoogle Scholar
  8. Schölmerich J, Gerbes AL, Andus T, Leser HG (1995) Spontane bakterielle Peritonitis bei Leberzirrhose mit Aszites. Dtsch Med Wochenschr 120: 454–461PubMedGoogle Scholar
  9. Schultheis KH, Rehm KE, Ecke H (Hrsg) (1991) Chirurgische Infektionen von Knochen, Gelenken und Weichteilen. De Gruyter, Berlin New YorkGoogle Scholar
  10. Simon C, Stille W (1999) Antibiotika-Therapie in Klinik und Praxis, 10. Aufl. Schattauer, StuttgartGoogle Scholar
  11. Wettstein M, Kudlek C, Häussinger D (2000) Spontan bakterielle Peritonitis. Diagnose, Therapie und Prophylaxe. Dtsch Ärztebl 47: B 2370–2373Google Scholar
  12. Winkeltau GJ (1995) Die diffuse Peritonitis. Grundlagen und Konzepte für eine differenzierte Therapie: Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  13. Wittmann D (1996) Duration of antibiotic treatment in surgical infection of the abdomen. Eur J Surg (Suppl): 19–23Google Scholar
  14. Zaleznik DF, Kasper DL (1998) Intraabdominal infections and abscesses. In: Fauci AS, Braunwald E, Isselbacher KJ et al. (eds) Harrison’s principles of internal medicine. McGraw-Hill, New York, pp 792–796Google Scholar

Literatur

  1. Adal KA, Cockerell CI, Petri WA Jr (1994) Cat scratch disease, bacillary angiomatosis and other infections due to Rochalimaea. N Engl J Med 350: 1509Google Scholar
  2. Bisno AL, Stevens DL (1996) Streptococcal infections of skin and soft tissues. N Engl J Med 334: 240–245CrossRefPubMedGoogle Scholar
  3. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control 20: 271–274CrossRefPubMedGoogle Scholar
  4. Kujath P, Eckmann C (1998) Die nekrotisierende Fasziitis und schwere Weichteilinfektionen durch Gruppe-A-Streptokokken. Diagnose, Therapie und Prognose. Dtsch Ärztebl 95: B 347–352Google Scholar
  5. Kuntz P, Pieringer-Müller E, Hof H (1996) Infektionsgefährdung durch Bissverletzungen. Dtsch Ärztebl 93: B 765–768Google Scholar
  6. Mader JT, Calhoun J (2000) Osteomyelitis. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, 1182–1200Google Scholar
  7. Nadal D, Zbinden R (1996) Erkrankungen durch Bartonellen. Internist 37: 890–894PubMedGoogle Scholar
  8. Norden C, Gillespie WJ, Nade S (eds) (1994) Infections in bones and joints. Blackwell Scientific Publications, BostonGoogle Scholar
  9. Norman C (2000) HIV and Africa’s future. Science 288(5474): 2149CrossRefPubMedGoogle Scholar
  10. Podbielski A, Rozdzinski E, Wiedeck H, Lütticken R (1998) Gruppe-A-Streptokokken und die nekrotisierende Fasziitis. Dtsch Ärztebl 95: B 353–359Google Scholar
  11. Priem S, Franz J, Krause A (1999) Ätiologie und Pathogenese bakteriell bedingter Arthritiden. Infektiöse Arthritis, reaktive Arthritis, Lyme-Arthritis. Internist 40: 936–944CrossRefPubMedGoogle Scholar
  12. Sander A, Kalibe T, Bredt W (1996) Bartonella (Rochalimaea)-Infektionen: Katzenkratzkrankheit und bazilläre Angiomatose. Dtsch Med Wochenschr 121: 65–69PubMedGoogle Scholar
  13. Schmidt KL (Hrsg) (2000) Checkliste Rheumatologie. Thieme, Stuttgart New YorkGoogle Scholar
  14. Simon C, Stille W (1999) Antibiotika-Therapie in Klinik und Praxis, 10. Aufl. Schattauer, StuttgartGoogle Scholar
  15. Smith JW, Hasan MS (2000) Infectious Arthritis. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, 1175–1182Google Scholar
  16. Steere AC (2001) Lyme Disease. N Engl J Med 345: 115–125CrossRefPubMedGoogle Scholar
  17. Swartz MN (2000) Myositis. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, 1058–1066Google Scholar

Copyright information

© Springer-Verlag Heidelberg 2005

Authors and Affiliations

  • Frank Bergmann
  • Ulrich Bienzle
  • Henning Breithaupt
  • Friedrich Grimminger
  • Jürgen Lohmeyer
  • D. Schürmann
  • Werner Seeger
  • Norbert Suttorp
  • Hans-Dieter Walmrath

There are no affiliations available

Personalised recommendations